In Vitro and In Vivo Activities of PD 0305970 and PD 0326448, New Bacterial Gyrase/Topoisomerase Inhibitors with Potent Antibacterial Activities versus Multidrug-Resistant Gram-Positive and Fastidious Organism Groups
- 1 April 2007
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (4) , 1191-1201
- https://doi.org/10.1128/aac.01321-06
Abstract
PD 0305970 and PD 0326448 are new bacterial gyrase and topoisomerase inhibitors (quinazoline-2,4-diones) that possess outstanding in vitro and in vivo activities against a wide spectrum of bacterial species including quinolone- and multidrug-resistant gram-positive and fastidious organism groups. The respective MICs (μg/ml) for PD 0305970 capable of inhibiting ≥90% of bacterial strains tested ranged from 0.125 to 0.5 versus staphylococci, 0.03 to 0.06 versus streptococci, 0.25 to 2 versus enterococci, and 0.25 to 0.5 versus Moraxella catarrhalis , Haemophilus influenzae , Listeria monocytogenes , Legionella pneumophila , and Neisseria spp. PD 0326448 MIC 90 s were generally twofold higher versus these same organism groups. Comparative quinolone MIC 90 values were 4- to 512-fold higher than those of PD 0305970. In testing for frequency of resistance, PD 0305970 and levofloxacin showed low levels of development of spontaneous resistant mutants versus both Staphylococcus aureus and Streptococcus pneumoniae . Unlike quinolones, which target primarily gyrA and parC , analysis of resistant mutants in S. pneumoniae indicates that the likely targets of PD 0305970 are gyrB and parE . PD 0305970 demonstrated rapid bactericidal activity by in vitro time-kill testing versus streptococci. This bactericidal activity carried over to in vivo testing, where PD 0305970 and PD 0326448 displayed outstanding Streptococcus pyogenes 50% protective doses (PD 50 s) (oral dosing) of 0.7 and 3.6 mg/kg, respectively (ciprofloxacin and levofloxacin PD 50 s were >100 and 17.7 mg/kg, respectively). PD 0305970 was also potent in a pneumococcal pneumonia mouse infection model (PD 50 = 3.2 mg/kg) and was 22-fold more potent than levofloxacin.Keywords
This publication has 15 references indexed in Scilit:
- 3-Aminoquinazolinediones as a New Class of Antibacterial Agents Demonstrating Excellent Antibacterial Activity Against Wild-Type and Multidrug Resistant OrganismsJournal of Medicinal Chemistry, 2006
- Lack of development of new antimicrobial drugs: a potential serious threat to public healthThe Lancet Infectious Diseases, 2005
- Recent advances in the treatment of Gram-positive infectionsDrug Discovery Today: Therapeutic Strategies, 2004
- Antibacterial resistance worldwide: causes, challenges and responsesNature Medicine, 2004
- New antibiotics for treatment of serious infections due to antibiotic-resistant Gram-positive cocciReviews in Medical Microbiology, 2004
- Manual of Clinical Microbiology, 8th Edition:Manual of Clinical Microbiology, 8th EditionClinical Infectious Diseases, 2004
- In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococciAntimicrobial Agents and Chemotherapy, 1995
- In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumoniaAntimicrobial Agents and Chemotherapy, 1990
- Comparative chemotherapeutic acitivity of new fluorinated 4-quinolones and standard agents against a variety of bacteria in a mouse infection modelJournal of Antimicrobial Chemotherapy, 1989
- Estimation of the ED50 and Its Error by Means of Logarithmic-Probit Graph Paper.Experimental Biology and Medicine, 1944